Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 70518-0122

17 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-0122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical Structure (Duloxetine 01)
Chemical structure of duloxetine hydrochloride, showing its molecular arrangement including aromatic rings, sulfur-containing thiophene, and amine hydrochloride components.*
FDA Label Image

Figure 1 (Duloxetine 02)

Figure 1 (Duloxetine 02)
A line graph showing the proportion of patients with relapse over time in days from randomization. It compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), indicating a lower relapse proportion for duloxetine over a period of approximately 200 days.*
FDA Label Image

Figure 2 (Duloxetine 03)

Figure 2 (Duloxetine 03)
A Kaplan-Meier curve showing the proportion of patients with relapse over time in days. It compares placebo treatment (dashed line) with duloxetine delayed-release capsules (solid line), illustrating a lower relapse rate over time for the duloxetine group.*
FDA Label Image

Figure 3 (Duloxetine 04)

Figure 3 (Duloxetine 04)
A line graph showing the percentage of patients improved against percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and Placebo, illustrating patient response levels across these treatments.*
FDA Label Image

Figure 4 (Duloxetine 05)

Figure 4 (Duloxetine 05)
Line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing trends across varying levels of pain improvement.*
FDA Label Image

Figure 5 (Duloxetine 06)

Figure 5 (Duloxetine 06)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares the effects of Duloxetine 60 mg taken twice daily, once daily, and placebo over a range of pain improvement percentages.*
FDA Label Image

Figure 6 (Duloxetine 07)

Figure 6 (Duloxetine 07)
A line graph showing percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine Delayed-Release dosages of 120 mg, 60 mg, and 20 mg once daily with placebo over a range of pain improvement percentages.*
FDA Label Image

Figure 7 (Duloxetine 08)

Figure 7 (Duloxetine 08)
A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares two groups: patients receiving 60 mg duloxetine once daily and those receiving placebo, illustrating the relationship between pain improvement and treatment over a range of improvement percentages.*
FDA Label Image

Figure 8 (Duloxetine 09)

Figure 8 (Duloxetine 09)
A line graph comparing the percentage of patients improved over various percent improvements in pain from baseline (BOCF). The graph shows two treatments: Placebo and Duloxetine Delayed-Release 60 mg/120 mg once daily, plotted as lines with marked data points representing patient improvement percentages.*
FDA Label Image

Figure 9 (Duloxetine 10)

Figure 9 (Duloxetine 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline using the BOCF method. It shows two lines representing placebo and Duloxetine Hydrochloride 60 mg once daily, tracking patient response decline as pain improvement percentage increases.*
FDA Label Image

Figure 10 (Duloxetine 11)

Figure 10 (Duloxetine 11)
A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two lines compare placebo and Duloxetine (60/120 mg once daily) treatments, illustrating greater patient improvement with Duloxetine across the pain improvement spectrum.*
FDA Label Image

Mm1 (Duloxetine 60mg 70518 0122 00)

Mm1 (Duloxetine 60mg 70518 0122 00)
Duloxetine Delayed-Release 60 mg capsules packaging label showing a quantity of 30 capsules. The label indicates the capsules are green and yellow. The product is repackaged by RemedyRepack Inc., with storage instructions included. Manufacturer information for Breckenridge, Boca Raton, FL, is also present along with a QR code.*
FDA Label Image

Mm2 (Duloxetine 60mg 70518 0122 01)

Mm2 (Duloxetine 60mg 70518 0122 01)
Duloxetine Delayed-Release 60 mg capsule packaging label for 30 capsules. The label shows the capsule color as green and yellow, with the manufacturer listed as RemedyRepack Inc., located in Indiana, PA. The label includes storage instructions and a QR code, with the product NDC 70518-0122-01 visible.*
FDA Label Image

Mm3 (Duloxetine 60mg 70518 0122 02)

Mm3 (Duloxetine 60mg 70518 0122 02)
Label for Duloxetine Delayed-Release Capsules, 60 mg strength. The carton indicates a quantity of 60 capsules with a green/yellow capsule color description. Labeler is RemedyRepack Inc., Indiana, PA. Storage instructions and a barcode are also visible. Manufacturer is Breckenridge, Boca Raton, FL.*
FDA Label Image

Mm4 (Duloxetine 60mg 70518 0122 03)

Mm4 (Duloxetine 60mg 70518 0122 03)
Label for Duloxetine Delayed-Release capsule, 60 mg strength. The package contains 100 capsules. The label shows the NDC number 70518-0122-03 and identifies the capsules as green and yellow. It is repackaged by RemedyRepack Inc. in Indiana, PA, with additional manufacturer information for Breckenridge, Boca Raton, FL. Storage instructions and typical warnings are included.*
FDA Label Image

Mm5 (Duloxetine 60mg 70518 0122 04)

Mm5 (Duloxetine 60mg 70518 0122 04)
Duloxetine Delayed-Release Capsule 60 mg label showing single capsule quantity. The capsule is green and yellow in color. The label includes the NDC number 70518-0122-04 and states it is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and manufacturing details by Breckenridge, Boca Raton, FL are present.*
FDA Label Image

Mm6 (Duloxetine 60mg 70518 0122 05)

Mm6 (Duloxetine 60mg 70518 0122 05)
Duloxetine Capsule Delayed-Release 60 mg, oral dosage form, packaged in a quantity of 90 capsules. The label includes storage instructions and repackaging information by RemedyRepack Inc., located in Indiana, PA. The capsule color is green and yellow, and the label shows the NDC number 70518-0122-05 and manufacturer details from Breckenridge, Boca Raton, FL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.